TY  - JOUR
AU  - Krljanac, Gordana
AU  - Ašanin, Milika
AU  - Mickovski-Katalina, Nataša
AU  - Milanović, Slađan
AU  - Bjekić, Jovana
AU  - Savić, Lidija
AU  - Mitrović, Predrag
AU  - Đurović, Marina
AU  - Vasiljević, Zorana
PY  - 2022
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1236
AB  - Background/Aim.The pharmacoinvasive (PI) therapy is a recommended strategy in patients (pts) with ST elevation myocardial infarction (STEMI) unable to undergo timely primary percutaneous coronary intervention (p-PCI). The aim of the study was to find out the cohorts of pts who are not treated by any reperfusion therapy (RT) as well to determine the outcome of the pts treated with RT in a transition country without fully applicable PI therapy. Methods. The study analyzed data from the Hospital National Registry for Acute Coronary Syndrome of Serbia (HORACS). Results. The significant predictors of the withdrawing of the application of any RT in the model [c 75.6%, SE 0.004, 95% CI 0.748-0.761)] were age (≥ 65 years), heart failure (Killip II-IV), diabetes mellitus, and the time to first medical contact (FMC) (> 360 min). In patients without RT, mortality was 15.7%, in pts treated with fibrinolytic therapy (FT) was 10.5%, and in pts treated with pPCI, it was 6.2% (p < 0.000). Within 3 hours to FMC, higher in-hospital mortality was in FT pts (FT 8.7% vs p-PCI 4.3%). FT treated patients were older, had more comorbidities and heart failure (HF). However, after propensity score matching, in order to adjust the differences among the pts, the mortality rate remained higher in FT pts but not statistically significantly higher than in p-PCI pts (FT 8.8% vs p-PCI 6.4%). Conclusion. The balance of the best cost-benefit strategies for better use of RT is difficult to achieve in transition countries. The possibility for timely p-PCI and PI therapy is especially not applicable in high-risk patients, older pts, pts with HF, and those with diabetes mellitus.
AB  - Uvod/Cilj. Preporuke za lečenje bolesnika sa akutnim infarktom miokarda sa elevacijom ST segmenta (STEMI), nalažu da se kod bolesnika koji ne mogu blagovremeno da odu na primarnu perkutanu intervenciju (p-PCI) primeni farmakoinvazivna (FI) strategija lečenja. Cilj rada bio je da se utvrde karakteristike bolesnika koji se uopšte ne leče reperfuzionom terapijom (RT), kao i da se analizira ishod lečenja pomoću RT, u zemlji u tranziciji u kojoj mreža za primenu FI terapije nije u potpunosti razvijena. Metode. Za istraživanje su korišćeni podaci bolničkog Nacionalnog registra za akutni koronarni sindrom Srbije (HORACS). Rezultati. Značajni prediktori za izostanak primene RT su prikazani u modelu (c 75,6%, SE0,004, 95% CI 0,748–0,761) u koji su uključene godine starosti (≥ 65), srčana insuficijencija (Killip klasa II-IV), dijabetes melitus, i vreme do prvog medicinskog kontakta (PMK) (> 360min). Kod bolesnika koji nisu bili lečeni RT, mortalitet je bio 15,7%, kod bolesnika lečenih fibrinolitičkom terapijom (FT) iznosio je 10,5%, a kod bolesnika lečenih p-PCI 6,2% ( p <0,000). U grupi bolesnika koji su do PMK stizali za 3 sata, mortalitet lečenih pomoću FT bio je veći od mortaliteta bolesnika lečenih p-PCI (FT 8,7% vs p-PCI 4,3%). Bolesnici lečeni pomoću FT bili su stariji, sa više komorbiditeta i sa učestalijim znacima srčane insuficijencije. Ipak, posle primenjenog propensity skora, sa ciljem da se izbegnu razlike između dve grupe bolesnika, mortalitet u FT grupi ostao je veći, alibez statistički značajne razlike u odnosu na bolesnike lečene p-PCI (FT 8,8%. vs p-PCI 6,4%). Zaključak. Primena RT, uz postignuti idealan balans potrošnje i koristi, teško je izvodljiva u zemljama u tranziciji. Mogućnosti za blagovremenu primenu p-PCI, kao i FIterapije, posebno su ograničene kod visoko rizičnih, starijih bolesnika, kod bolesnika sa znacima srčane insuficijencije, komorbiditetima i dijabetesom melitusom.
PB  - Military Medical Academy, INI
T2  - Vojnosanitetski Pregled
T1  - The use of reperfusion therapy in transition countries without fully applicable pharmacoinvasive strategy
EP  - 229
IS  - 3
SP  - 221
VL  - 79
DO  - 10.2298/VSP190118090K
ER  - 

@article{
author = "Krljanac, Gordana and Ašanin, Milika and Mickovski-Katalina, Nataša and Milanović, Slađan and Bjekić, Jovana and Savić, Lidija and Mitrović, Predrag and Đurović, Marina and Vasiljević, Zorana",
year = "2022",
abstract = "Background/Aim.The pharmacoinvasive (PI) therapy is a recommended strategy in patients (pts) with ST elevation myocardial infarction (STEMI) unable to undergo timely primary percutaneous coronary intervention (p-PCI). The aim of the study was to find out the cohorts of pts who are not treated by any reperfusion therapy (RT) as well to determine the outcome of the pts treated with RT in a transition country without fully applicable PI therapy. Methods. The study analyzed data from the Hospital National Registry for Acute Coronary Syndrome of Serbia (HORACS). Results. The significant predictors of the withdrawing of the application of any RT in the model [c 75.6%, SE 0.004, 95% CI 0.748-0.761)] were age (≥ 65 years), heart failure (Killip II-IV), diabetes mellitus, and the time to first medical contact (FMC) (> 360 min). In patients without RT, mortality was 15.7%, in pts treated with fibrinolytic therapy (FT) was 10.5%, and in pts treated with pPCI, it was 6.2% (p < 0.000). Within 3 hours to FMC, higher in-hospital mortality was in FT pts (FT 8.7% vs p-PCI 4.3%). FT treated patients were older, had more comorbidities and heart failure (HF). However, after propensity score matching, in order to adjust the differences among the pts, the mortality rate remained higher in FT pts but not statistically significantly higher than in p-PCI pts (FT 8.8% vs p-PCI 6.4%). Conclusion. The balance of the best cost-benefit strategies for better use of RT is difficult to achieve in transition countries. The possibility for timely p-PCI and PI therapy is especially not applicable in high-risk patients, older pts, pts with HF, and those with diabetes mellitus., Uvod/Cilj. Preporuke za lečenje bolesnika sa akutnim infarktom miokarda sa elevacijom ST segmenta (STEMI), nalažu da se kod bolesnika koji ne mogu blagovremeno da odu na primarnu perkutanu intervenciju (p-PCI) primeni farmakoinvazivna (FI) strategija lečenja. Cilj rada bio je da se utvrde karakteristike bolesnika koji se uopšte ne leče reperfuzionom terapijom (RT), kao i da se analizira ishod lečenja pomoću RT, u zemlji u tranziciji u kojoj mreža za primenu FI terapije nije u potpunosti razvijena. Metode. Za istraživanje su korišćeni podaci bolničkog Nacionalnog registra za akutni koronarni sindrom Srbije (HORACS). Rezultati. Značajni prediktori za izostanak primene RT su prikazani u modelu (c 75,6%, SE0,004, 95% CI 0,748–0,761) u koji su uključene godine starosti (≥ 65), srčana insuficijencija (Killip klasa II-IV), dijabetes melitus, i vreme do prvog medicinskog kontakta (PMK) (> 360min). Kod bolesnika koji nisu bili lečeni RT, mortalitet je bio 15,7%, kod bolesnika lečenih fibrinolitičkom terapijom (FT) iznosio je 10,5%, a kod bolesnika lečenih p-PCI 6,2% ( p <0,000). U grupi bolesnika koji su do PMK stizali za 3 sata, mortalitet lečenih pomoću FT bio je veći od mortaliteta bolesnika lečenih p-PCI (FT 8,7% vs p-PCI 4,3%). Bolesnici lečeni pomoću FT bili su stariji, sa više komorbiditeta i sa učestalijim znacima srčane insuficijencije. Ipak, posle primenjenog propensity skora, sa ciljem da se izbegnu razlike između dve grupe bolesnika, mortalitet u FT grupi ostao je veći, alibez statistički značajne razlike u odnosu na bolesnike lečene p-PCI (FT 8,8%. vs p-PCI 6,4%). Zaključak. Primena RT, uz postignuti idealan balans potrošnje i koristi, teško je izvodljiva u zemljama u tranziciji. Mogućnosti za blagovremenu primenu p-PCI, kao i FIterapije, posebno su ograničene kod visoko rizičnih, starijih bolesnika, kod bolesnika sa znacima srčane insuficijencije, komorbiditetima i dijabetesom melitusom.",
publisher = "Military Medical Academy, INI",
journal = "Vojnosanitetski Pregled",
title = "The use of reperfusion therapy in transition countries without fully applicable pharmacoinvasive strategy",
pages = "229-221",
number = "3",
volume = "79",
doi = "10.2298/VSP190118090K"
}

Krljanac, G., Ašanin, M., Mickovski-Katalina, N., Milanović, S., Bjekić, J., Savić, L., Mitrović, P., Đurović, M.,& Vasiljević, Z.. (2022). The use of reperfusion therapy in transition countries without fully applicable pharmacoinvasive strategy. in Vojnosanitetski Pregled
Military Medical Academy, INI., 79(3), 221-229.
https://doi.org/10.2298/VSP190118090K

Krljanac G, Ašanin M, Mickovski-Katalina N, Milanović S, Bjekić J, Savić L, Mitrović P, Đurović M, Vasiljević Z. The use of reperfusion therapy in transition countries without fully applicable pharmacoinvasive strategy. in Vojnosanitetski Pregled. 2022;79(3):221-229.
doi:10.2298/VSP190118090K .

Krljanac, Gordana, Ašanin, Milika, Mickovski-Katalina, Nataša, Milanović, Slađan, Bjekić, Jovana, Savić, Lidija, Mitrović, Predrag, Đurović, Marina, Vasiljević, Zorana, "The use of reperfusion therapy in transition countries without fully applicable pharmacoinvasive strategy" in Vojnosanitetski Pregled, 79, no. 3 (2022):221-229,
https://doi.org/10.2298/VSP190118090K . .

TY  - JOUR
AU  - Vasiljević, Zorana
AU  - Dimković, Nada
AU  - Lazarević, Katarina
AU  - Burmazović, Snežana
AU  - Krstić, Nebojša
AU  - Milanović, Slađan
AU  - Zorić, Svetlana
AU  - Micić, Dragan
PY  - 2013
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/493
AB  - Introduction. Losartan, the angiotensin type 1 receptor blocker (ARB) exercises its main antihypertensive effect by vasodilatation of peripheral arteries. Objective. The aim of this study was to evaluate the antihypertensive effect and safety of losartan in patients with mild and moderate arterial hypertension (AH). Methods. This was an open post-marketing study with losartan as monotherapy in previously treated or untreated patients with AH. Primary efficacy parameter was the percentage of patients that achieved target blood pressure after 8-week treatment with a single daily dose of losartan of 50-100 mg. Safety parameters were assessed according to the percentage of adverse events and metabolic effects of therapy. Results. The study included 550 patients with AH (59% female and 41% male), mean age 56.8±11.4 years, BMI=27±4 kg/m2. Losartan was applied in 31% of untreated and 69% of previously treatment-resistant patients After 8 weeks target blood pressure was achieved in 67.8% (SBP) and in 81.1% (DBP) of patients, respectively. The mean decrease was 21.8% for SBP and 21.1% for DBP (p lt 0.001). Out of all, 65% of patients achieved both target SBP and DBP values. Hydrochlorothiazide was added to the therapy in 11.6% of patients. There were no significant differences in drug efficacy between the entire group and subgroups of patients with diabetes mellitus and impaired renal function (p=ns). Adverse events were rare and metabolic effect was favorable. Conclusion. Monotherapy with losartan in a dosage of 50-100 mg applied during 8 weeks resulted in achieving target values of blood pressure in 65% of patient with mild and moderate hypertension, also including the patients with diabetes mellitus and impaired renal function. Losartan is a safe and metabolically neutral medication.
AB  - Uvod. Losartan, blokator angiotenzinskog receptora tip 1 (ARB), antihipertenzivni efekat ostvaruje vazodilatacijom perifernih arterija. Cilj rada. Cilj studije je bio da se procene efikasnost i bezbednost primene losartana kod bolesnika s arterijskom hipertenzijom blagog i umerenog stepena. Metode rada. U otvorenoj postmarketinškoj studiji losartan je primenjen kao monoterapija kod bolesnika s prethodno lečenom ili nelečenom umerenom i blagom hipertenzijom tokom osam nedelja u dozi od 50 mg i 100 mg jednom dnevno, uz posmatranje promene procenta bolesnika kod kojih su dostignute ciljne vrednosti sistolnog (SAP) i dijastolnog arterijskog krvnog pritiska (DAP). Bezbednost primene leka procenjena je prema procentu neželjenih dejstava i metaboličkim efektima terapije. Rezultati. U studiju je uključeno 550 bolesnika (59% žena i 41% muškaraca) prosečne starosti od 56,8±11,4 godine i prosečnog indeksa telesne mase (BMI) od 27±4 kg/m2. Losartan je primenjen kod 31% nelečenih i 69% prethodno lečenih bolesnika ali s neregulisanom hipertenzijom. Posle osam nedelja ciljne vrednosti SAP su postignute kod 67,8% bolesnika, a DAP kod 81,1% (i SAP i DAP kod 65% bolesnika), s prosečnim smanjenjem SAP od 21,8% i DAP od 21,1% (p lt 0,001). Hidrohlorotijazid je dodat terapiji kod samo 11,6% bolesnika. Terapijski efekti se nisu statistički značajno razlikovali između svih bolesnika i podgrupa ispitanika sa dijabetes melitusom (DM) i smanjenom funkcijom bubrega. Neželjena dejstva leka su bila retka, a metabolički efekat bio je povoljan. Zaključak. Monoterapija losartanom dovodi do postizanja ciljnih vrednosti krvnog pritiska kod 65% bolesnika sa blagom i umerenom hipertenzijom tokom osam nedelja primene, uključujući i bolesnike sa DM i sa smanjenom funkcijom bubrega. Losartan je siguran i metabolički neutralan lek.
PB  - Srpsko lekarsko društvo, Beograd
T2  - Srpski arhiv za celokupno lekarstvo
T1  - Postmarketing study of efficacy and safety of losartan during the treatment of patients with mild and moderate hypertension: Lothar study
T1  - Postmarketinška studija efikasnosti i bezbednosti primene losartana u lečenju bolesnika s umerenom i blagom arterijskom hipertenzijom - studija Lotnar
EP  - 28
IS  - 1-2
SP  - 22
VL  - 141
DO  - 10.2298/SARH1302022V
ER  - 

@article{
author = "Vasiljević, Zorana and Dimković, Nada and Lazarević, Katarina and Burmazović, Snežana and Krstić, Nebojša and Milanović, Slađan and Zorić, Svetlana and Micić, Dragan",
year = "2013",
abstract = "Introduction. Losartan, the angiotensin type 1 receptor blocker (ARB) exercises its main antihypertensive effect by vasodilatation of peripheral arteries. Objective. The aim of this study was to evaluate the antihypertensive effect and safety of losartan in patients with mild and moderate arterial hypertension (AH). Methods. This was an open post-marketing study with losartan as monotherapy in previously treated or untreated patients with AH. Primary efficacy parameter was the percentage of patients that achieved target blood pressure after 8-week treatment with a single daily dose of losartan of 50-100 mg. Safety parameters were assessed according to the percentage of adverse events and metabolic effects of therapy. Results. The study included 550 patients with AH (59% female and 41% male), mean age 56.8±11.4 years, BMI=27±4 kg/m2. Losartan was applied in 31% of untreated and 69% of previously treatment-resistant patients After 8 weeks target blood pressure was achieved in 67.8% (SBP) and in 81.1% (DBP) of patients, respectively. The mean decrease was 21.8% for SBP and 21.1% for DBP (p lt 0.001). Out of all, 65% of patients achieved both target SBP and DBP values. Hydrochlorothiazide was added to the therapy in 11.6% of patients. There were no significant differences in drug efficacy between the entire group and subgroups of patients with diabetes mellitus and impaired renal function (p=ns). Adverse events were rare and metabolic effect was favorable. Conclusion. Monotherapy with losartan in a dosage of 50-100 mg applied during 8 weeks resulted in achieving target values of blood pressure in 65% of patient with mild and moderate hypertension, also including the patients with diabetes mellitus and impaired renal function. Losartan is a safe and metabolically neutral medication., Uvod. Losartan, blokator angiotenzinskog receptora tip 1 (ARB), antihipertenzivni efekat ostvaruje vazodilatacijom perifernih arterija. Cilj rada. Cilj studije je bio da se procene efikasnost i bezbednost primene losartana kod bolesnika s arterijskom hipertenzijom blagog i umerenog stepena. Metode rada. U otvorenoj postmarketinškoj studiji losartan je primenjen kao monoterapija kod bolesnika s prethodno lečenom ili nelečenom umerenom i blagom hipertenzijom tokom osam nedelja u dozi od 50 mg i 100 mg jednom dnevno, uz posmatranje promene procenta bolesnika kod kojih su dostignute ciljne vrednosti sistolnog (SAP) i dijastolnog arterijskog krvnog pritiska (DAP). Bezbednost primene leka procenjena je prema procentu neželjenih dejstava i metaboličkim efektima terapije. Rezultati. U studiju je uključeno 550 bolesnika (59% žena i 41% muškaraca) prosečne starosti od 56,8±11,4 godine i prosečnog indeksa telesne mase (BMI) od 27±4 kg/m2. Losartan je primenjen kod 31% nelečenih i 69% prethodno lečenih bolesnika ali s neregulisanom hipertenzijom. Posle osam nedelja ciljne vrednosti SAP su postignute kod 67,8% bolesnika, a DAP kod 81,1% (i SAP i DAP kod 65% bolesnika), s prosečnim smanjenjem SAP od 21,8% i DAP od 21,1% (p lt 0,001). Hidrohlorotijazid je dodat terapiji kod samo 11,6% bolesnika. Terapijski efekti se nisu statistički značajno razlikovali između svih bolesnika i podgrupa ispitanika sa dijabetes melitusom (DM) i smanjenom funkcijom bubrega. Neželjena dejstva leka su bila retka, a metabolički efekat bio je povoljan. Zaključak. Monoterapija losartanom dovodi do postizanja ciljnih vrednosti krvnog pritiska kod 65% bolesnika sa blagom i umerenom hipertenzijom tokom osam nedelja primene, uključujući i bolesnike sa DM i sa smanjenom funkcijom bubrega. Losartan je siguran i metabolički neutralan lek.",
publisher = "Srpsko lekarsko društvo, Beograd",
journal = "Srpski arhiv za celokupno lekarstvo",
title = "Postmarketing study of efficacy and safety of losartan during the treatment of patients with mild and moderate hypertension: Lothar study, Postmarketinška studija efikasnosti i bezbednosti primene losartana u lečenju bolesnika s umerenom i blagom arterijskom hipertenzijom - studija Lotnar",
pages = "28-22",
number = "1-2",
volume = "141",
doi = "10.2298/SARH1302022V"
}

Vasiljević, Z., Dimković, N., Lazarević, K., Burmazović, S., Krstić, N., Milanović, S., Zorić, S.,& Micić, D.. (2013). Postmarketing study of efficacy and safety of losartan during the treatment of patients with mild and moderate hypertension: Lothar study. in Srpski arhiv za celokupno lekarstvo
Srpsko lekarsko društvo, Beograd., 141(1-2), 22-28.
https://doi.org/10.2298/SARH1302022V

Vasiljević Z, Dimković N, Lazarević K, Burmazović S, Krstić N, Milanović S, Zorić S, Micić D. Postmarketing study of efficacy and safety of losartan during the treatment of patients with mild and moderate hypertension: Lothar study. in Srpski arhiv za celokupno lekarstvo. 2013;141(1-2):22-28.
doi:10.2298/SARH1302022V .

Vasiljević, Zorana, Dimković, Nada, Lazarević, Katarina, Burmazović, Snežana, Krstić, Nebojša, Milanović, Slađan, Zorić, Svetlana, Micić, Dragan, "Postmarketing study of efficacy and safety of losartan during the treatment of patients with mild and moderate hypertension: Lothar study" in Srpski arhiv za celokupno lekarstvo, 141, no. 1-2 (2013):22-28,
https://doi.org/10.2298/SARH1302022V . .

Kostić, P., Novičić, D., Blesić, S., Vasiljević, Z., Grujić-Milanović, J., Pavlović, S.,& Milanović, S.. (2011). Semantic Search Engine as tool for clinical decision support in Register for Acute Coronary Syndrome. in Telfor Journal
Društvo za telekomunikacije, Beograd i Akademska misao, Beograd., 3(1), 66-71.
https://hdl.handle.net/21.15107/rcub_rimi_381

Kostić P, Novičić D, Blesić S, Vasiljević Z, Grujić-Milanović J, Pavlović S, Milanović S. Semantic Search Engine as tool for clinical decision support in Register for Acute Coronary Syndrome. in Telfor Journal. 2011;3(1):66-71.
https://hdl.handle.net/21.15107/rcub_rimi_381 .

Kostić, Pavle, Novičić, Dejan, Blesić, Suzana, Vasiljević, Zorana, Grujić-Milanović, Jelica, Pavlović, Siniša, Milanović, Slađan, "Semantic Search Engine as tool for clinical decision support in Register for Acute Coronary Syndrome" in Telfor Journal, 3, no. 1 (2011):66-71,
https://hdl.handle.net/21.15107/rcub_rimi_381 .

TY  - JOUR
AU  - Vasiljević, Zorana
AU  - Mickovski-Katalina, Nataša
AU  - Krljanac, Gordana
AU  - Panić, Gordana
AU  - Putniković, Biljana
AU  - Ostojić, Miodrag
AU  - Stojanović, Bojan
AU  - Milanović, Slađan
PY  - 2011
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/343
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - Journal of Cardiovascular Medicine
T1  - Coronary care unit and primary percutaneous coronary intervention networks improve the standard of care: reperfusion therapy in ST elevation myocardial infarction in Serbia from 2002 to 2008
EP  - 302
IS  - 4
SP  - 300
VL  - 12
DO  - 10.2459/JCM.0b013e328343e9f2
ER  - 

@article{
author = "Vasiljević, Zorana and Mickovski-Katalina, Nataša and Krljanac, Gordana and Panić, Gordana and Putniković, Biljana and Ostojić, Miodrag and Stojanović, Bojan and Milanović, Slađan",
year = "2011",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Journal of Cardiovascular Medicine",
title = "Coronary care unit and primary percutaneous coronary intervention networks improve the standard of care: reperfusion therapy in ST elevation myocardial infarction in Serbia from 2002 to 2008",
pages = "302-300",
number = "4",
volume = "12",
doi = "10.2459/JCM.0b013e328343e9f2"
}

Vasiljević, Z., Mickovski-Katalina, N., Krljanac, G., Panić, G., Putniković, B., Ostojić, M., Stojanović, B.,& Milanović, S.. (2011). Coronary care unit and primary percutaneous coronary intervention networks improve the standard of care: reperfusion therapy in ST elevation myocardial infarction in Serbia from 2002 to 2008. in Journal of Cardiovascular Medicine
Lippincott Williams & Wilkins, Philadelphia., 12(4), 300-302.
https://doi.org/10.2459/JCM.0b013e328343e9f2

Vasiljević Z, Mickovski-Katalina N, Krljanac G, Panić G, Putniković B, Ostojić M, Stojanović B, Milanović S. Coronary care unit and primary percutaneous coronary intervention networks improve the standard of care: reperfusion therapy in ST elevation myocardial infarction in Serbia from 2002 to 2008. in Journal of Cardiovascular Medicine. 2011;12(4):300-302.
doi:10.2459/JCM.0b013e328343e9f2 .

Vasiljević, Zorana, Mickovski-Katalina, Nataša, Krljanac, Gordana, Panić, Gordana, Putniković, Biljana, Ostojić, Miodrag, Stojanović, Bojan, Milanović, Slađan, "Coronary care unit and primary percutaneous coronary intervention networks improve the standard of care: reperfusion therapy in ST elevation myocardial infarction in Serbia from 2002 to 2008" in Journal of Cardiovascular Medicine, 12, no. 4 (2011):300-302,
https://doi.org/10.2459/JCM.0b013e328343e9f2 . .